AbbVie Inc.
Moat Score — AbbVie Inc.
Total Moat Score
16 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | AbbVie's business is built entirely on patent-protected, FDA-approved biologics (Skyrizi, Rinvoq, Botox) that face years of regulatory exclusivity before generic or biosimilar competition — the core moat mechanism of the branded pharmaceutical industry. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | AbbVie is not a low-cost producer; it competes on drug efficacy and differentiation rather than manufacturing cost, and carries heavy R&D and commercial infrastructure spend typical of large biopharma. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | Patent-protected immunology and neuroscience drugs command premium list prices and AbbVie has successfully repriced its portfolio around Skyrizi and Rinvoq post-Humira, though U.S. IRA drug-price negotiation is a growing constraint on future pricing power. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical efficacy and prescribing decisions are independent of how many other patients use a given drug, so there is no network effect. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Physician prescribing habits, patient treatment stability, and payer formulary placement create meaningful inertia once a patient is established on a therapy, but biosimilar and generic substitution (as seen with Humira) can override this once exclusivity lapses. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Large pharma is a competitive field with many well-funded rivals (J&J, Novartis, Amgen, Eli Lilly) racing for the same disease areas; AbbVie's edge comes from patent timing and pipeline execution rather than a structurally under-competed market. |